91 related articles for article (PubMed ID: 10023718)
1. Human mismatch repair gene (hMSH2) product expression in relation to recurrence of transitional cell carcinoma of the urinary bladder.
Jin TX; Furihata M; Yamasaki I; Kamada M; Liang SB; Ohtsuki Y; Shuin T
Cancer; 1999 Jan; 85(2):478-84. PubMed ID: 10023718
[TBL] [Abstract][Full Text] [Related]
2. Expression of the human mismatch repair gene hMSH2: a potential marker for urothelial malignancy.
Leach FS; Hsieh JT; Molberg K; Saboorian MH; McConnell JD; Sagalowsky AI
Cancer; 2000 May; 88(10):2333-41. PubMed ID: 10820356
[TBL] [Abstract][Full Text] [Related]
3. [Expression of mismatch repair gene hMSH2 in human malignant ovarian tumors and its clinical significance].
Ma L; Zhang J; Peng Z
Zhonghua Fu Chan Ke Za Zhi; 2000 May; 35(5):291-3. PubMed ID: 11775911
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of microsatellite instability determined by immunohistochemical staining of hMSH2 and hMSH6 in urothelial carcinoma of the bladder.
Mylona E; Zarogiannos A; Nomikos A; Giannopoulou I; Nikolaou I; Zervas A; Nakopoulou L
APMIS; 2008 Jan; 116(1):59-65. PubMed ID: 18254781
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability.
Catto JW; Xinarianos G; Burton JL; Meuth M; Hamdy FC
Int J Cancer; 2003 Jul; 105(4):484-90. PubMed ID: 12712438
[TBL] [Abstract][Full Text] [Related]
6. Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer.
Prtilo A; Leach FS; Markwalder R; Kappeler A; Burkhard FC; Cecchini MG; Studer UE; Thalmann GN
J Urol; 2005 Nov; 174(5):1814-8; discussion 1818. PubMed ID: 16217293
[TBL] [Abstract][Full Text] [Related]
7. Expression of the mismatch repair protein hMSH2 in carcinoma in situ and invasive cancer of the breast.
Bock N; Meden H; Regenbrecht M; Jünemann B; Wangerin J; Marx D
Anticancer Res; 2000; 20(1A):119-24. PubMed ID: 10769643
[TBL] [Abstract][Full Text] [Related]
8. Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis.
Friedrich MG; Toma MI; Petri S; Cheng JC; Hammerer P; Erbersdobler A; Huland H
Eur Urol; 2004 Jun; 45(6):737-43. PubMed ID: 15149745
[TBL] [Abstract][Full Text] [Related]
9. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
[TBL] [Abstract][Full Text] [Related]
10. Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder.
Elsamman E; Fukumori T; Kasai T; Nakatsuji H; Nishitani MA; Toida K; Ali N; Kanayama HO
BJU Int; 2006 Jun; 97(6):1202-7. PubMed ID: 16686711
[TBL] [Abstract][Full Text] [Related]
11. Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma.
Ross JS; del Rosario AD; Bui HX; Kallakury BV; Okby NT; Figge J
Mod Pathol; 1996 Aug; 9(8):854-60. PubMed ID: 8871928
[TBL] [Abstract][Full Text] [Related]
12. Cyclical change of hMSH2 protein expression in normal endometrium during the menstrual cycle and its overexpression in endometrial hyperplasia and sporadic endometrial carcinoma.
Hamid AA; Mandai M; Konishi I; Nanbu K; Tsuruta Y; Kusakari T; Kariya M; Kita M; Fujii S
Cancer; 2002 Feb; 94(4):997-1005. PubMed ID: 11920468
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
14. The mismatch repair gene hMSH2 is mutated in the prostate cancer cell line LNCaP.
Leach FS; Velasco A; Hsieh JT; Sagalowsky AI; McConnell JD
J Urol; 2000 Nov; 164(5):1830-3. PubMed ID: 11025778
[TBL] [Abstract][Full Text] [Related]
15. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Schlott T; Korabiowska M; Käthei N; Zöller G; Glaser F; Kunze E
Anticancer Res; 2004; 24(5A):2745-56. PubMed ID: 15517881
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
Dekairelle AF; Tombal B; Cosyns JP; Gala JL
Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
[TBL] [Abstract][Full Text] [Related]
17. Expression of the human mismatch repair gene hMSH2 in normal and neoplastic tissues.
Leach FS; Polyak K; Burrell M; Johnson KA; Hill D; Dunlop MG; Wyllie AH; Peltomaki P; de la Chapelle A; Hamilton SR; Kinzler KW; Vogelstein B
Cancer Res; 1996 Jan; 56(2):235-40. PubMed ID: 8542572
[TBL] [Abstract][Full Text] [Related]
18. [Expression of bcl-2 and p16 in transitional cell carcinoma of urinary bladder].
Leng J; Zhang Y; Yao X; Wen K
Zhonghua Wai Ke Za Zhi; 2000 Jan; 38(1):40-3. PubMed ID: 11831985
[TBL] [Abstract][Full Text] [Related]
19. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
Mahnken A; Kausch I; Feller AC; Krüger S
Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
[TBL] [Abstract][Full Text] [Related]
20. Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma.
Fromont G; Rouprêt M; Amira N; Sibony M; Vallancien G; Validire P; Cussenot O
Eur Urol; 2005 Nov; 48(5):764-70. PubMed ID: 16126329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
